# Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review

Page: https://stenobird.com/podcast/hematologic-oncology-update-916423/bispecific-antibodies-in-the-management-of-lymphoma-ash-2025-review
Text version: https://stenobird.com/podcast/hematologic-oncology-update-916423/bispecific-antibodies-in-the-management-of-lymphoma-ash-2025-review.md
Podcast: [Hematologic Oncology Update](https://stenobird.com/podcast/hematologic-oncology-update-916423)
Published: 2026-01-21T19:30:00+00:00
Episode link: https://hematologic-oncology.captivate.fm/episode/5606-ashbispecificslymphoma25
Audio file: https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/2a2c2fe2-09a8-435e-b24d-9c07220c6366.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/bispecific-antibodies-in-the-management-of-lymphoma-ash-2025-review
Duration seconds: 3672

## Resource

Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma. CME information and select publications here .

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/bispecific-antibodies-in-the-management-of-lymphoma-ash-2025-review/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/hematologic-oncology-update-916423/bispecific-antibodies-in-the-management-of-lymphoma-ash-2025-review.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.